Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 6/20 | 0.38 |
| ▸ | UGCG | Q16739 | 6/20 | 0.38 |
| ▸ | GBA2 | Q9HCG7 | 6/20 | 0.38 |
| ▸ | LCT | P09848 | 3/20 | 0.38 |
| ▸ | MGAM | O43451 | 2/20 | 0.38 |
| ▸ | SI | P14410 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007962 | 0.84 | IDO1 (0.49) | IDO1FFAR1 | |
| SCHEMBL1009874 | 0.82 | IDO1 (0.50) | IDO1GBA1UGCGGBA2LCT | |
| SCHEMBL1008512 | 0.77 | GBA1 (0.52) | IDO1GBA1UGCGGBA2 | |
| SCHEMBL584278 | 0.77 | IDO1 (0.51) | IDO1FFAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3156002 | 0.75 | IDO1 (0.63) | IDO1FFAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1005828 | 0.75 | IDO1 (0.47) | IDO1GBA1UGCGGBA2LCT | |
| SCHEMBL9472054 | 0.74 | IDO1 (0.49) | IDO1GBA1UGCGGBA2SLC6A4 | |
| SCHEMBL1007471 | 0.74 | MAP2K1 (0.35) | GBA1UGCGGBA2LCTMGAM | |
| SCHEMBL5042108 | 0.74 | IDO1 (0.56) | IDO1FFAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7561874 | 0.74 | IDO1 (0.55) | IDO1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280935-B1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8673946-B2 | 4-trimethylammonio-butyrates as CPT2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130030033-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8349893-B2 | 4-trimethylammonio-butyrates as CPT2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8344027-B2 | 4-dimethylaminobutyric acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | ANDJELKOVIC MIRJANA (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2280935-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132979-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | IDO1 1380/4885FFAR1 162/4885GBA1 915/4885 |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | IDO1 1846/4885FFAR1 125/4885GBA1 1705/4885 |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | IDO1 1380/4885FFAR1 162/4885GBA1 915/4885 |
| US-20130030033-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | IDO1 1846/4885FFAR1 125/4885GBA1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.